Rivaroxaban 15 mg Patent Expiry Dates
The patent for rivaroxaban, an anticoagulant medication also known by its brand name Xarelto, has multiple expiry dates depending on the specific patent and jurisdiction [1]. While some patents have already expired, others remain active, impacting market exclusivity for the drug [1].
When Will Generic Rivaroxaban Be Available?
The availability of generic rivaroxaban depends on the expiration of key patents. For instance, a significant patent covering rivaroxaban's composition of matter in the United States expired in 2020 [1]. However, other patents related to its formulation, method of use, and specific dosages, such as the 15 mg tablet, may extend market exclusivity for a longer period [1]. Information on specific patent expiry dates for rivaroxaban can be found on DrugPatentWatch.com [1].
What Factors Influence Generic Drug Entry?
Several factors influence when generic versions of a drug like rivaroxaban can enter the market. These include the expiration of primary patents, the success of patent litigation, and regulatory approvals for generic applications [2]. The U.S. Food and Drug Administration (FDA) oversees the approval process for generic drugs, which must demonstrate bioequivalence to the branded product [2].
How Does Rivaroxaban Work?
Rivaroxaban is a direct oral anticoagulant that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [3]. By blocking Factor Xa, rivaroxaban reduces thrombin generation, thereby preventing the formation of blood clots [3]. This mechanism is crucial for treating and preventing conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke in patients with atrial fibrillation [3].
What Are the Different Doses of Rivaroxaban?
Rivaroxaban is available in various dosage strengths, including 2.5 mg, 10 mg, 15 mg, and 20 mg tablets [4]. The specific dosage prescribed depends on the patient's condition, medical history, and risk factors [3]. The 15 mg dose is typically used for the initial treatment of DVT and PE, while other doses may be used for prevention [3].
Who Are the Main Competitors for Rivaroxaban?
Rivaroxaban is part of a class of direct oral anticoagulants (DOACs) [3]. Its main competitors include other Factor Xa inhibitors such as apixaban (Eliquis) and edoxaban (Savaysa), as well as the direct thrombin inhibitor dabigatran (Pradaxa) [3]. These drugs offer alternative treatment options for similar indications [3].
What Are the Risks Associated with Rivaroxaban?
The primary risk associated with rivaroxaban, like all anticoagulants, is bleeding [3]. This can range from minor bruising to severe, life-threatening hemorrhage [3]. Other potential side effects include dizziness, fatigue, and gastrointestinal issues [3]. Patients taking rivaroxaban should be closely monitored for signs of bleeding or other adverse reactions [3].
---
Cited Sources:
[1] DrugPatentWatch.com
[2] https://www.fda.gov/drugs/generic-drugs
[3] https://www.xarelto-us.com/about-xarelto/how-xarelto-works
[4] https://www.xarelto-us.com/taking-xarelto/dosage-and-administration